MPN

— A most probable number (MPN) method capable of estimating as campylobacters per 100 ml of water is described. The method gave results close to those obtained by the viable count method of Miles, Misra & Irwin (1938) with graded suspensions of Campylobacter jejuni.

— Findings from an observational retrospective study1 evaluating the outcome of patients with accelerated‐phase or blast‐phase myeloproliferative neoplasms (AP/BP-MPNs) who received azacitidine monotherapy or in combination revealed a median overall survival (OS) of 8.04 months after a median follow-up of 15 months, particularly for those without high-risk genetic features. Overall, OS was lower in patients with BP vs AP (6.24 vs 18.0 months; P = .03), complex karyotype (6.0 vs 13.08 months; P =.005), and TP53 mutation (8.0 vs 11.0 months; P =.009), respectively.

— In an MPN, the bone marrow overproduces one or more types of blood cells like red blood cells, white blood cells, or platelets. This can lead to conditions like Polycythemia Vera, which involves too many red blood cells, or essential thrombocythemia, which is an overproduction of platelets. These are often chronic diseases that progress slowly.